July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
How does atropine inhibit myopia development? Evidence from animal studies.
Author Affiliations & Notes
  • William K Stell
    Cumming School of Medicine, University of Calgary, Okotoks, Alberta, Canada
  • Footnotes
    Commercial Relationships   William Stell, Novartis Pharmaceuticals Corporation. (F), Novartis Pharmaceuticals Corporation. (C), Novartis Pharmaceuticals Corporation. (R)
  • Footnotes
    Support  Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (#RGPIN/131-2013) and the Foundation Fighting Blindness Canada EyeGeye Research Training Fund to WKS, and trainees’ studentships from various sources.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3294. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      William K Stell; How does atropine inhibit myopia development? Evidence from animal studies.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3294.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Atropine is well known to prevent or slow the progression of myopia, in experimental animal models (form-deprivation myopia [FDM] and negative-lens-induced myopia [LIM]) as well as in naturally occurring human myopia. Given that atropine is known mainly as a competitive antagonist at muscarinic acetylcholine receptors (mAChR), it is widely assumed that this property is responsible for its anti-myopia effect. Myopia in a wide range of animal species (birds and mammals, including Homo sapiens) is inhibited by atropine, but not in every individual case; and surprisingly high doses are required for maximal effectiveness. I will review evidence from my lab suggesting that mAChRs may not be the target by which atropine and some other anti-muscarinic drugs inhibit myopia-development.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×